Press Enter to search · Esc to close
The same peptide class that reshaped weight loss is now stacking evidence in kidney protection, fibrosis prevention, and transplant medicine. Here's what the data actually says.
Nephrologists are floating a new diagnostic umbrella — Metabolic Kidney Disease — to catch the quiet damage that obesity, insulin resistance and fatty liver inflict on kidneys years before standard tests flag a problem.
The disease formerly known as fatty liver got a new name in 2023 — and a fresh acknowledgment that it rarely travels alone. Here's what the latest review tells us about the liver-kidney link.
A multinational cohort sketches who's really starting GLP-1s for diabetes and kidney disease — and a new mouse study hints these drugs may rewire taste itself.
The shots that started as diabetes medicine and became weight-loss icons are quietly rewriting their own job description. The 2025 evidence points to a multi-organ story — with caveats worth knowing.
The shots that started as diabetes drugs and exploded as weight-loss icons are turning out to do a lot more than mute hunger. New research traces their fingerprints across the hindbrain, the kidney's salt switches, and the hormone that tells you it's lunchtime.
The same peptide class everyone's whispering about in the locker room is showing up in neurology, nephrology, and orthopedic data. The signal looks real — but moderate, not miraculous.
A new meta-analysis confirms GLP-1 drugs protect the heart and kidneys. Real-world data suggests pairing them with SGLT2 inhibitors may compound the benefit — with caveats worth understanding.
The blockbuster weight-loss drug is being studied for far more than the scale. Here's what the newest research actually shows — and where the evidence still thins out.